Company News Environmental
What are bioprocess containers?
Used daily across the scientific research and pharmaceutical industries, biocontainers have an extensive range of uses that help to streamline […]
Nov 05th, 2024
Sartorius Stedim Biotech reported double-digit gains in sales revenue and earning during the first quarter of 2016.
The successful start to the year continues the gains the leading international laboratory and pharmaceutical equipment supplier made during 2015.
Dr. Joachim Kreuzburg, chief executive officer at Sartorius, said “dynamic growth” was being driven “by both divisions and all business regions.”
“Our larger Bioprocess Solutions Division has continued to perform excellently”, he added. “Regionally, business in the Americas has been expanding the most as projected. Based on our first-quarter results, we confirm our ambitious targets that we have set for the full year of 2016.”
According to official figures, sales revenues rose 20.9% in the first quarter.
The strong operating performance was buoyed by the recent acquisitions of BioOutsource (April 2015) and Cellca (July 2015). Both acquisitions contributed 3 percentage points to growth.
View full press release